Cover Image
Market Research Report

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

Published by GBI Research Product code 244540
Published Content info 97 Pages
Immediate Delivery Available
Price
Back to Top
Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth
Published: June 12, 2012 Content info: 97 Pages
Description

Summary

GBI Research, a leading business intelligence provider, has released its latest research "Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth" which examines two major trends already impacting on marketing strategies in the global pharmaceutical environment. These trends are the rise in importance of biologic products as replacements for the traditional small-molecule drugs in pharmaceutical pipelines, and the emergence of new national markets driven by seismic shifts now taking place among the leading national markets in the global economy. The report discusses the strategies the industry needs to embrace to address these internal and external challenges.

GBI Research analysis highlights the trends in the biologic sector, with their impact on the therapy of a wide range of diseases, and the routes taken by companies to improve their presence in the biologic sector and maximize their product lifecycle management to ensure future growth and shareholder value.

The report offers a thorough analysis of the newly-emerging national markets, including not only the leading BRIC economies but also those economies dubbed "fast followers". In an evolving market environment where an increasing proportion of products currently in late stage clinical development in pharmaceutical companies are biologics, this report discusses the opportunities for building success on these novel approaches in those markets which are set to feature prominently among the top national economies in the very near future.

Scope

  • The report describes major classes of biologic medicines, with their therapeutic applications and importance.
  • Significant pipeline developments now in advanced clinical trials are identified.
  • Major companies already present in the biologic arena are profiled.
  • The BRIC markets (Brazil, Russia, India and China) are described in detail, covering their importance as pharmaceutical markets.
  • Relevant background for each country, including healthcare provision, pricing and government policies towards foreign companies, is provided.
  • A general country analysis for each is also included, covering political, economic, social, technological, legislative and environmental aspects.
  • Four other "pharmerging" economies are also discussed in some detail.
  • Trends of importance to pharma market planners are discussed, as well as strategies important to foreign companies seeking a foothold in these markets.

Reasons to buy

  • Identify the key market opportunities with specific reference to the growth of biologics, so that you can align R&D portfolios to maximize growth
  • Develop optimal business strategies on a country-by-country basis, taking account of national market drivers and restraints
  • Devise a tailored R&D approach to address specific geographical and therapeutic demands
  • Develop key strategic initiatives based on your company's pharma R&D strengths and their best deployment in a changing pharmaceutical world
  • Re-evaluate and reassess investment decisions and explore ways in which to diversify and optimise market penetration vis-a-vis the pharmerging economies.

Executive Summary

BRIC Nations to Outgrow Traditional Markets in Biologics

Biologics industry growth in the BRIC countries (Brazil, Russia, India and China) is expected to outpace traditional markets, according to a new report by business intelligence providers GBI Research.

The report* states that, until recently, these emerging markets did not figure in the plans of the major pharmaceutical companies, but due to financial and political developments they are now seen as important countries in the pharmaceutical industry.

In terms of growth, it is anticipated that the BRIC countries will outstrip traditional markets like Europe and the US, albeit from a lower revenue base, in the years to come.

GBI Research reports these burgeoning economies are projected to account for over a quarter of the global biological market revenues by 2015.

The biologic sector is increasingly important to the pharma industry due to stagnation in R&D productivity and concerns over the so-called "patent cliff", with an established first generation of biologic therapies representing 24 of the top selling pharmaceutical products worldwide.

While the patent cliff has largely affected small-molecule synthetic drugs which have been the staple of pharmaceutical prosperity for decades, biologic treatments are emerging as a greater standard of care and are more difficult to replicate and manufacture.

These therapies are biological rather than chemical developments that promise greater effectiveness due to their capacity to target the underlying cause of disease and form personalized medicines.

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

This report discusses the growing importance of biologics and emerging markets. The key classes of biologic medicines are described, along with their therapeutic applications and importance.

In addition, significant pipeline developments in advanced clinical trials are identified. Selected companies that are already present in the biologic field are also profiled in this report.

Furthermore, the BRIC markets are described in detail. This covers their importance as pharmaceutical markets, including relevant background information such as pricing and government policies towards foreign companies, and provides a general country analysis for each.

Trends of importance to pharmaceutical market planners are also discussed, as well as strategies that are relevant for foreign companies seeking to gain a foothold in these markets.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Biological Strategies in the Emerging Markets - Introduction

  • 2.1. Emergence of New National Markets
  • 2.2. Shift in Emphasis Towards Biologicals
  • 2.3. Obsolescence of Blockbusters
  • 2.4. What Defines a Biological Product?
  • 2.5. Why do Companies Want to Introduce Biologicals in BRIC Markets?
  • 2.6. What Biological Products are Currently Available and in What Therapy Areas?
    • 2.6.1. Monoclonal Antibodies
    • 2.6.2. Anti-cancer mAbs
    • 2.6.3. Anti-TNF
    • 2.6.4. Therapeutic Proteins
    • 2.6.5. Insulin
    • 2.6.6. Erythropoietin
    • 2.6.7. Growth Hormone
    • 2.6.8. Cytokines
    • 2.6.9. Blood Factors
    • 2.6.10. Market Status of Therapeutic Proteins
    • 2.6.11. Vaccines
  • 2.7. What are the Most Attractive Emerging Markets for Biologicals?
    • 2.7.1. Market Size
    • 2.7.2. Price Considerations
    • 2.7.3. Government Attitudes

3. Biological Strategies in the Emerging Markets - Market Characterization and Forecasts

  • 3.1. Market Size in BRIC Countries
    • 3.1.1. Brazil
    • 3.1.2. Russia
    • 3.1.3. India
    • 3.1.4. China
  • 3.2. Market Size in Second-tier Emerging Markets
    • 3.2.1. Mexico
    • 3.2.2. Turkey
    • 3.2.3. South Korea
    • 3.2.4. South Africa
    • 3.2.5. Other Emerging Markets
  • 3.3. BRIC Market Forecasts
  • 3.4. Conclusions

4. Biological Strategies in the Emerging Markets - Market Drivers And Restraints

  • 4.1. Summary of National Markets
    • 4.1.1. Brazil
    • 4.1.2. Russia
    • 4.1.3. India
    • 4.1.4. China
  • 4.2. Meeting Clinical Needs
  • 4.3. Government Controls - Price and Product Access
    • 4.3.1. Brazil
    • 4.3.2. Russia
    • 4.3.3. India
    • 4.3.4. China
  • 4.4. PESTLE Analyses
    • 4.4.1. Brazil
    • 4.4.2. Russia
    • 4.4.3. India
    • 4.4.4. China
  • 4.5. Overall Conclusions

5. Biological Strategies in the Emerging Markets - Regulatory Landscape

  • 5.1. Overview of Regulatory Environment in the BRIC countries
    • 5.1.1. Brazil
    • 5.1.2. Russia
    • 5.1.3. India
    • 5.1.4. China
  • 5.2. Regulations in Other Emerging Markets
    • 5.2.1. Turkey
    • 5.2.2. South Korea
  • 5.3. Intellectual Property in BRIC Markets
    • 5.3.1. Brazil
    • 5.3.2. Russia
    • 5.3.3. India
    • 5.3.4. China
  • 5.4. Future of IP in BRIC Markets
  • 5.5. Patents
  • 5.6. Conclusions

6. Biological Strategies in the Emerging Markets - Trend Analysis

  • 6.1. Demographic and Disease Trends
    • 6.1.1. Aging Populations
    • 6.1.2. Unmet Clinical Needs
    • 6.1.3. Immune Openings for Biologics
    • 6.1.4. Growing Incidence of Cancer
    • 6.1.5. R&D Challenges and Changes
    • 6.1.6. M&As Build Pipelines and Profitability
  • 6.2. Pricing Trends
    • 6.2.1. Flexibility
  • 6.3. Regulatory Trends
  • 6.4. National Market Trends
  • 6.5. Conclusions

7. Biological Strategies in the Emerging Markets - Pipeline Analysis

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cancer mAbs
  • 7.4. Cancer - Therapeutic Proteins
  • 7.5. Diabetes
  • 7.6. Hormone Therapies
  • 7.7. Hemopoietic Therapies
  • 7.8. Immune Disease
  • 7.9. Overall Conclusions

8. Biological Strategies in the Emerging Markets - Company Analysis

  • 8.1. Introduction
  • 8.2. Hoffman-La Roche
    • 8.2.1. Biologics
    • 8.2.2. Presence in BRIC Markets
  • 8.3. Novo Nordisk
    • 8.3.1. Biologics
    • 8.3.2. Presence in BRIC Markets
  • 8.4. Johnson & Johnson
    • 8.4.1. Biologics
    • 8.4.2. Presence in BRIC Markets
  • 8.5. Sanofi
    • 8.5.1. Biologics
    • 8.5.2. Presence in BRIC Markets
  • 8.6. Eli Lilly
    • 8.6.1. Biologics
    • 8.6.2. Presence in BRIC Markets
  • 8.7. Sandoz
    • 8.7.1. Biologics
    • 8.7.2. Presence in BRIC Markets
  • 8.8. Teva
    • 8.8.1. Biologics
    • 8.8.2. Presence in BRIC Markets
  • 8.9. Conclusions

9. Biological Strategies in the Emerging Markets - Business Strategies

  • 9.1. Launch Strategies
    • 9.1.1. Timing of Launch
    • 9.1.2. Innovative Drug Launch
    • 9.1.3. Comprehensive Launch Plan
    • 9.1.4. Pricing Strategy versus Affordability
    • 9.1.5. Healthcare Access versus Uptake
    • 9.1.6. No "One Size Fits All" Policy
  • 9.2. Marketing Strategies
    • 9.2.1. Brazil
    • 9.2.2. Russia
    • 9.2.3. India
    • 9.2.4. China
  • 9.3. Pricing Strategies
    • 9.3.1. Brazil
    • 9.3.2. Russia
    • 9.3.3. India
    • 9.3.4. China
  • 9.4. Partnering Strategies
    • 9.4.1. Brazil
    • 9.4.2. Russia
    • 9.4.3. India
    • 9.4.4. China
  • 9.5. Manufacturing Strategies
  • 9.6. Competition
  • 9.7. Outlook
  • 9.8. Overall Conclusions

10. Biological Strategies in the Emerging Markets - Appendix

  • 10.1. Key Definitions
  • 10.2. Abbreviations (in alphabetical order)
  • 10.3. Sources
  • 10.4. Methodology
    • 10.4.1. Primary Research
    • 10.4.2. Secondary Research
  • 10.5. Contacts Us
  • 10.6. Disclaimer

List of Tables

  • Table 1: Biological Strategies in the Emerging Markets, Leading Cancer Mabs, 2011
  • Table 2: Biological Strategies in the Emerging Markets, Leading Approved Cytokines, 2010
  • Table 3: Biological Strategies in the Emerging Markets, Brazil, Core Statistics, 2010
  • Table 4: Biological Strategies in the Emerging Markets, Brazil, Foreign Investments, 2010
  • Table 5: Biological Strategies in the Emerging Markets, Russia, Core Statistics, 2010
  • Table 6: Biological Strategies in the Emerging Markets, Russia, Foreign Investments, 2010
  • Table 7: Biological Strategies in the Emerging Markets, India, Core Statistics
  • Table 8: Biological Strategies in the Emerging Markets, China, Core Statistics, 2010
  • Table 9: Biological Strategies in the Emerging Markets, China, Foreign Investments, 2010
  • Table 10: Biological Strategies in the Emerging Markets, Pharmaceutical Market and Biological Sector ($bn), 2010-2015
  • Table 11: Biological Strategies in the Emerging Markets, Russia, Most Harmful Diseases, 2010
  • Table 12: Biological Strategies in the Emerging Markets, Brazil, PESTLE Analysis Summary, 2010
  • Table 13: Biological Strategies in the Emerging Markets, Russia, PESTLE Analysis Summary, 2010
  • Table 14: Biological Strategies in the Emerging Markets, Russia, PESTLE Analysis Summary, 2010
  • Table 15: Biological Strategies in the Emerging Markets, China, PESTLE Analysis Summary, 2010
  • Table 16: Biological Strategies in the Emerging Markets, Brazil, Recognized Drug Classes, 2010
  • Table 17: Biological Strategies in the Emerging Markets, BRIC Nations, Pharmaceutical Expenditure By Payer, 2009
  • Table 18: Biological Strategies in the Emerging Markets, Global, Contribution of Pharmaceutical Market Growth, 2005, 2008, 2013
  • Table 19: Biological Strategies in the Emerging Markets, Global, Number of New General Drugs in Development, 2010
  • Table 20: Biological Strategies in the Emerging Markets, Global Therapeutic Biologics Pipeline (%), 2010
  • Table 21: Biological Strategies in the Emerging Markets, Leading Therapeutics Proteins in Clinical Development Worldwide to Treat Cancer, 2011
  • Table 22: Biological Strategies in the Emerging Markets, Leading Therapeutics Proteins in Clinical Development Worldwide to Treat Cancer, 2011
  • Table 23: Biological Strategies in the Emerging Markets, Leading Diabetes Molecules in Clinical Development Worldwide to Treat Cancer, 2011
  • Table 24: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Hormonal Conditions, 2011
  • Table 25: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Hemopoietic Conditions, 2011
  • Table 26: Biological Strategies in the Emerging Markets, Biopharmaceutical Drugs in Clinical Development Worldwide to Treat Immuno-inflammatory Diseases, 2011
  • Table 27: Biological Strategies in the Emerging Markets, Leading Biologics Sales ($bn), 2010
  • Table 28: Biological Strategies in the Emerging Markets, Sales of Roche's Leading Biologics ($bn), 2010
  • Table 29: Biological Strategies in the Emerging Markets, Sales of Novo's Leading Biologics ($bn), 2010
  • Table 30: Biological Strategies in the Emerging Markets, Sales of J&J's Leading Biologics ($bn), 2010
  • Table 31: Biological Strategies in the Emerging Markets, Sales of Sanofi's Leading Biologics ($bn), 2010
  • Table 32: Biological Strategies in the Emerging Markets ,Sales of Lilly's Leading Biologics ($bn), 2010
  • Table 33: Biological Strategies in the Emerging Markets, Sales of Sandoz's Leading Biologics ($bn), 2010
  • Table 34: Biological Strategies in the Emerging Markets, Sales of Teva's Leading Biologics ($bn), 2010
  • Table 35: Biological Strategies in the Emerging Markets , Recent Acquisitions in the Biologics Arena, 2011
  • Table 36: Biological Strategies in the Emerging Markets, Russia, Strategic Alliances, 2011
  • Table 37: Biological Strategies in the Emerging Markets, India, Strategic Alliances, 2011

List of Figures

  • Figure 1: Biological Strategies in the Emerging Markets, Global Mabs Therapeutic Sales Based on Prescription Usage, 2010
  • Figure 2: Biological Strategies in the Emerging Markets, Global , Market Share of Therapeutic Proteins (%), 2010
  • Figure 3: Biological Strategies in the Emerging Markets, China, Factors Stimulating Pharmaceutical Sales Growth, 2010
  • Figure 4: Biological Strategies in the Emerging Markets, Leading Chinese Companies with a Commitment to Developing R&D-Based Products, 2010
  • Figure 5: Biological Strategies in the Emerging Markets, BRIC Nations, Pharmaceutical Expenditure By Payer (%), 2009
  • Figure 6: Biological Strategies in the Emerging Markets, Global, Contribution of Pharmaceutical Market Growth (%), 2005, 2008, 2013
  • Figure 7: Biological Strategies in the Emerging Markets, Global Therapeutic Biologics Pipeline (%), 2010
  • Figure 8: Biological Strategies in the Emerging Markets, the US, Products in Development to Treat Cancer, 2010
  • Figure 9: Biological Strategies in the Emerging Markets, Important Factors for Launching Biologics, 2011
Back to Top